GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Equity-to-Asset

Helix BioPharma (TSX:HBP) Equity-to-Asset : -0.75 (As of Jan. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Helix BioPharma's Total Stockholders Equity for the quarter that ended in Jan. 2024 was C$-0.26 Mil. Helix BioPharma's Total Assets for the quarter that ended in Jan. 2024 was C$0.34 Mil.

The historical rank and industry rank for Helix BioPharma's Equity-to-Asset or its related term are showing as below:

TSX:HBP' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.34   Med: 0.18   Max: 0.89
Current: -0.75

During the past 13 years, the highest Equity to Asset Ratio of Helix BioPharma was 0.89. The lowest was -4.34. And the median was 0.18.

TSX:HBP's Equity-to-Asset is ranked worse than
91.73% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs TSX:HBP: -0.75

Helix BioPharma Equity-to-Asset Historical Data

The historical data trend for Helix BioPharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Equity-to-Asset Chart

Helix BioPharma Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.49 0.49 -0.34 0.09 -0.82

Helix BioPharma Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.58 -0.82 0.33 -0.75

Competitive Comparison of Helix BioPharma's Equity-to-Asset

For the Biotechnology subindustry, Helix BioPharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Equity-to-Asset falls into.



Helix BioPharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Helix BioPharma's Equity to Asset Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Equity to Asset (A: Jul. 2023 )=Total Stockholders Equity/Total Assets
=-0.844/1.029
=

Helix BioPharma's Equity to Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

Equity to Asset (Q: Jan. 2024 )=Total Stockholders Equity/Total Assets
=-0.259/0.344
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Helix BioPharma  (TSX:HBP) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Helix BioPharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma (TSX:HBP) Business Description

Traded in Other Exchanges
Address
401 Bay Street, Suite 2704, Toronto, ON, CAN, M5H 2Y
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.